Halozyme Therapeutics Inc

HALO remains in a constructive Stage 2 uptrend above rising EMAs but shows a Bullish Exhaustion signal and overbought readings. Price is currently pulling back into the 9- and 20-day EMAs, offering a potential re-entry zone. The medium-term bias stays bullish, yet short-term timing is unfavorable, so execution should be deferred until a clear hold or rejection off the EMA zone.

• ↑Total revenue up 48% YoY to $481 M, driven by 50% royalty growth.
• ↑FY26 revenue guide raised 31–37% to $1.835–1.91 B, reflecting robust outlook.
• ↓Weak book-to-price ratio indicates potential valuation headwinds.